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Treatment of triple negative breast cancer (TNBC)-associated metastasis represents an unmet clinical 
need, and we lack effective therapeutics for a disease that exhibits high relapse rates and associates with 
poor patient outcomes. Advanced nanosized drug delivery systems may enhance the efficacy of first-line 
chemotherapeutics by altering drug pharmacokinetics and enhancing tumor/metastasis targeting to signif-
icantly improve efficacy and safety. Herein, we propose the application of injectable poly-amino acid-
based nanogels (NGs) as a versatile hydrophilic drug delivery platform for the treatment of TNBC lung 
metastasis. We prepared biocompatible and biodegradable cross-linked NGs from polyglutamic acid 
(PGA) loaded with the chemotherapeutic agent doxorubicin (DOX). Our optimized synthetic procedures 
generated NGs of ~100 nm in size and 25 wt% drug loading content that became rapidly internalized in 
TNBC cell lines and displayed IC50 values comparable to the free form of DOX. Importantly, PGA-DOX 
NGs significantly inhibited lung metastases and almost completely suppressed lymph node metastases in 
a spontaneously metastatic orthotopic mouse TNBC model. Overall, our newly developed PGA-DOX 




















Nanogels (NGs, nanometer-sized gels) have drawn significant recent attention as pharmaceutical 
nanocarriers as they possess advantageous characteristics of both hydrogels and nanoparticles.1-3 NGs 
represent a versatile hydrophilic drug delivery platform for the controlled site-specific release of hydro-
phobic drugs and biomacromolecules such as proteins or nucleic acids.4 Due to their inherent porosity, 
NGs also offer unusually high drug loading capacities compared to liposomes or polymeric micelles and 
can incorporate greater than 30% wt of a given cargo. Furthermore, the swelling properties of NGs allow 
for controlled cargo release in response to several environmental stimuli (e.g., ionic strength, pH, or tem-
perature).5-7 In this sense, NGs that display stimuli-responsive cargo release in the tumor microenviron-
ment are especially appealing.8-10 
The physico-chemical properties of the three-dimensional cross-linked nanoscale polymer network of 
NGs, such as size, charge, porosity, softness, amphiphilic character, and degradability, can be varied by 
chemical composition (polymer and cross-linking agents) to allow a range of potential biological appli-
cations; however, few NGs have reached clinical trials, and NGs have yet to meet approval. This unfor-
tunate circumstance partly derives from the low mechanical and biological stability of NGs under physi-
ological conditions based on physical interactions.11 Nevertheless, chemically cross-linked NGs have the 
potential to overcome said limitations and become more widely applied, even in intravenous administra-
tions.11 In this context, cross-linked polypeptides and poly-amino acid (PAA)-based NGs can surpass 
many of the problems associated with other NGs, including those related to solubility, scalability, repro-
ducibility, biodegradability, administration, and long-term accumulation.  
Biodegradable and biocompatible PAA-based polymers12 can be synthesized in a scalable and repro-
ducible manner by controlled polymerization techniques, and an ever-increasing number of examples 
reaching preclinical and clinical stages has highlighted their relevance to drug delivery.12 Of particular 
interest, poly-L-glutamic acid (PGA) represent a promising candidate, with a PGA-paclitaxel conjugate 
(Opaxio®) and several other anticancer PGA-based micelles currently in advanced clinical trials.13  
 
The use of PAAs in the preparation of NGs has been limited to the formation of electrostatic complexes 
with polycationic entities,14,15 or the cross-linking of a polymeric micelle core composed of polyethylene 
glycol (PEG)-PAA block copolymers.16-18 Furthermore, the implementation of PAAs in NGs for the treat-
ment of metastasis has yet to be explored in any great depth19 with no examples of a breast cancer-asso-
ciated metastasis targeted PAA-based NG therapeutic. 
The triple negative breast cancer subtype (TNBC, lacks estrogen receptors, progesterone receptors, 
and HER2 expression) represents about 10-20% of all breast cancer diagnoses. The aggressive character-
istics of TNBC include metastasis to regional lymph nodes and distant organs and high relapse rates, 
which combine to foster an overall poorer prognosis when compared with other subtypes.20 Lung metas-
tasis represents a recurrent complication, occurring in 60-70% of all breast cancer patients, and a leading 
cause of patient deaths.21 Meanwhile, the metastatic load of lymph nodes represents an important prog-
nostic factor and frequently decides therapy choice.22,23 
Herein, we describe the first example of anionic chemically-crosslinked NGs exclusively formed from 
the biodegradable and biocompatible PGA polymer. We employed copper-catalyzed azide-alkyne cy-
cloaddition (CuAAC)24 to prepare cross-linked PGA NGs in inverse miniemulsion, thus allowing control 
over size and dispersity (Scheme 1). Importantly, we designed PGA NGs to become rapidly degraded in 
the presence of Cathepsin B, a lysosomal enzyme that also is overexpressed in the stroma of certain types 
of tumors, to promote tumor-specific drug release (bioresponsiveness). Following loading with the chem-
otherapy agent doxorubicin (DOX), we explored the potential for our bioresponsive PGA-DOX NG-based 
strategy to treat TNBC-associated lung and lymph node metastases in a murine model. Encouragingly, we 
discovered that PGA-DOX NGs exert antitumor activity in vivo and, more importantly, a significant anti-






Scheme 1. Synthesis and mode of action of bioresponsive cross-linked PGA-DOX NGs  
 
2. Materials and Methods 
Materials 
All chemicals, cells, animals, and materials used in this study are fully described in the Electronic Sup-
porting Information (ESI). 
Physicochemical Characterization 
Information regarding NMR spectroscopy, circular dichroism (CD), dynamic light scattering (DLS), z-
potential analysis, Fourier-transform infrared spectroscopy (FT-IR), ultraviolet-visible (UV-Vis) spectros-
copy, scanning electron microscopy (SEM), atomic force microscopy (AFM), and cryo-transmission elec-
tron microscopy (Cryo-TEM) measurements and experimental conditions can be found in the ESI. 
Synthesis of Alkyne- and Azide-derivatized PGA Precursors 
PGA precursors were synthesized according to Barz et al.25 and provided yields of 80-90% and conjuga-
tion efficiencies of 90-100%. The ESI contains the chemical structures (Scheme S1) as well as additional 
details. 




Several reaction parameters were evaluated to explore the most suitable CuAAC conditions for the cou-
pling of PGA-azide and PGA-alkyne precursors. More specifically, polymers 1 and 3 (Table S1) were 
selected, and CuAAC coupling was performed in H2O. A representative example (see Entry 4 in Table 1) 
is described as follows: 3 mg of PGA-N3 (10% functionalization, compound 1, 1.65 µmol of N3 groups), 
7.5 mg of PGA-Alkyne (10% functionalization, compound 3, 4.95 µmol of Alkyne groups), and 6.09 mg 
of NaHCO3 (1.1 eq of per COOH group) were dissolved in an aqueous solution of CuSO4 (0.05 M, 66 
µL). After stirring, 165 µL of a 0.1 M sodium ascorbate solution was added. The mixture was allowed to 
react at 40 ºC for 48 h protected from light. The crude product was then purified using Amicon centrifugal 
filters, and then lyophilized and analyzed by 1H NMR and IR spectroscopies.  
Preparation of PGA-based NGs by CuAAC Crosslinking in Miniemulsion 
NGs were synthesized by CuAAC cross-linking using a miniemulsion technique to template NG for-
mation. In a representative example, PGA-co-EG(n)N3 glutamate 10% (1 in Scheme S1, 21 mg, 1 eq of 
N3 groups, 11.5 µmol), PGA-co-propargyl glutamate (3 in Scheme S1, 34.8 mg, 2 eq of alkyne groups, 
23 µmol), and NaHCO3 (23.6 mg, 1.1 eq per carboxylic acid group) were dissolved in 340 µL of MilliQ 
water. Freshly prepared aqueous solutions of CuSO4 (46 µL, 0.2 eq per N3) and sodium ascorbate (115 
µL, 1 eq per N3) were added. Immediately afterward, the aqueous solution was mixed with 15 mL of 
cyclohexane containing Tween® 80 (100 mg) and Span® 80 (300 mg). The mixture was then ultrasoni-
cated with a Branson Digital Sonifier (2 × 2 min at 50% intensity), yielding a stable emulsion. DLS 
measurements were performed following ultrasonication to check nanodroplet size and dispersity. The 
resulting emulsion was stirred at 40 °C for 48 h, and then 15 mL of cyclohexane was added, and the 
solution was centrifuged (30 min, 6000 rpm). A gel-like precipitate was observed; the supernatant was 
then removed, and fresh cyclohexane was added. This procedure was repeated three times to remove 
surfactants. After complete solvent drying, MilliQ water was added, and the resulting solution was dia-
lyzed (MWCO 50 KDa) or washed extensively using Amicon centrifugal filters (MWCO 50 KDa). To 




(2 ×), NaHCO3 (2 ×), and Milli Q water (4 ×). The resulting NGs (31 mg) were analyzed by DLS (2 
mg/mL in H2O, filtered by 0.45 µm nylon filters), AFM, SEM, cryo-TEM, IR, and 1H NMR. Finally, the 
resulting NGs were freeze-dried or stored in solution at 4 °C.  
General Procedures for the Preparation of PGA-DOX NGs 
DOX·HCl was dissolved at 3 mg/mL in a mixture of 10 mM NaH2PO4, 1 M HCl, and DMSO (100:1:5.5). 
PGA NGs were separately dissolved at 2.5 mg/mL in 10 mM Na2HPO4, 1 M NaOH (100:1). Both solu-
tions were mixed (0.75 mg DOX per mg of NG), and pH measured, adjusted to pH 7 if necessary, and 
stirred overnight protected from the light. PGA-DOX NGs were purified by extensively washing using 
Amicon Ultra-15 centrifugal filters (MWCO 50 KDa) until no red solution was observed, and subse-
quently freeze-dried. After purification, NGs were run through a Sephadex G25 column (1 mL) to verify 
the absence of free DOX. The amount of encapsulated DOX was estimated by UV-Vis spectroscopy in 
H2O (λ = 488 nm, ε = 11,500 L mol-1 cm-1, ESI). Mass recoveries varied between 10 and 30%.  
Drug Release and Plasma Stability 
Drug release profiles were analyzed following a previously described procedure.27 Briefly, 2 mg of NGs 
were weighed and separately dissolved in 20 mM acetate buffer pH 6 containing EDTA, Dithiothreitol 
(DTT), and Cathepsin B (final concentration 4.16 units/mL), PBS pH 5.5 (10 mM, 150 mM NaCl),  PBS 
pH 7.4 (10 mM, 150 mM NaCl, Figure S6) or mouse plasma.  DTT and EDTA solutions were added as 
optimal Cathepsin B activity requires pH < 6 and a reductive environment. NGs were placed in a bath at 
37 ºC with magnetic stirring. At specified time intervals, aliquots were taken and run through a small (0.9 
mL) Sephadex G25 column in MilliQ water. Free DOX was retained in the upper part of the column, 
while NGs could be collected, freeze-dried, dissolved in Milli Q water, and analyzed by UV-Vis to deter-






All biological procedures employed in this study are fully described in the ESI, including cell culture 
protocols, MTS assays for cell viability, cellular uptake by flow cytometry, confocal fluorescence micros-
copy, Annexin V by flow cytometry, cell cycle by flow cytometry, tumor model, determination of metas-
tases, and Western blot analyses.  
 
3. Results and Discussion 
Preparation of Injectable PGA NGs with suitable Physico-chemical Properties 
For the development of PGA NGs, we synthesized a series of alkyne- and azide-derivatized PGAs 
as a first step (as previously described by us in Barz et al.25) using a PGA with a molecular weight (Mw) 
of 10,500 Da and polydispersity (PDI) of 1.1.28 We employed propargylamine and oligoethylene glycol 
azide residues for alkyne and azide functionalization, respectively, to yield compounds with orthogonal 
functionalities (see Scheme 1, Scheme S1, and Table S1 in the ESI).  
CuAAC is a simple and powerful coupling technology for the conjugation of polymers and other 
macromolecules; nevertheless, the presence of Cu traces represents a potential concern. Therefore, we 
optimized the CuAAC coupling conditions in aqueous solution before the preparation of NGs to yield 
enhanced cross-linking efficiency while using the minimum amount of catalyst. Moreover, we established 
efficient protocols to remove trace Cu, as demonstrated by MTT assays (Section 3c, ESI). 
We evaluated several reaction conditions to define those steps required for efficient PGA-
azide/PGA-alkyne coupling for the different PGA precursors (Table 1). More specifically, we selected 
polymers 1 and 3 (Table S1) and performed CuAAC coupling in H2O, employing 1.1 eq of NaHCO3 per 
COOH group.26 We fixed the reaction time at 48 h and performed a set of reactions changing the reaction 
temperature, the amount of copper catalyst, and the ratio between azide and alkyne functional groups. The 




groups to facilitate reaction monitoring by following the disappearance of the signal at ca. 3.4 ppm (char-
acteristic of the methylene protons adjacent to the azide groups) in the 1H NMR spectra, as well as by the 
appearance of the triazole peak at ca. 8.0 ppm (Figure 1a). 
Moreover, we employed IR spectroscopy to monitor the disappearance of the intense characteristic 
azide signal at 2100 cm-1 (Figure 1b). Following the optimization of the CuAAC conditions, we assessed 
a series of PGA precursors (compounds 1-5, Table S1) that displayed different degrees of functionalization 
(10%, 17% for both azide and alkyne building blocks, compounds 1-4 in Table S1) and then evaluated the 
effect of short PEG linkers of different lengths (6 and 2 units, compounds 1 and 2 vs. 5 in Table S1). We 
hypothesized that both parameters could affect coupling efficiency through the CuAAC reaction; how-
ever, we obtained PGA-PGA copolymers in all cases (Entries 6-8 in Table 1).  
 
Table 1. PGA precursors and CuAAC conditions assessed 






1 2/1 10/10 0.05/0.25 rt 
2 1/2 10/10 0.05/0.25 rt 
3 1/2 10/10 0.20/1 rt 
4 3/1 10/10 0.20/1 40 
5 1/2 10/10 0.20/1 40 
6 3/1 17/17 0.20/1 40 
7 3/1 10/18 0.20/1 40 
8 3/1 17/10 0.20/1 40 
aDegree of functionalization of PGA polymers (compounds 1-5 in Table S1). bEquivalents calculated per N3 group 
 
In the next step, we screened several PGA precursors with different degrees of functionalization 
to synthesize NGs suitable for biological applications, i.e., with adequate size, stability, and low PDI. 
Furthermore, we wanted to explore the effect of a higher cross-linking degree on NG size, stability, and 




We obtained NGs by CuAAC cross-linking using inverse miniemulsion, a technique that allows 
the creation of stable nanodroplets in a continuous phase by applying high shear stress, such as those 
associated with ultrasonication. Subsequently, the cross-linking takes place inside the nanodroplets, and 
we finally obtained NGs after extensive purification in cyclohexane and MilliQ water.  
DLS analysis demonstrated that combinations of polymers with similar functionalization degrees 
resulted in NGs with lower PDI values. PGA precursors with 10 % functionalization (NG 1 in Table 2, 
prepared from compounds 1 and 3 in Table S1) represented one of the most promising combinations in 
terms of PDI and reproducibility. We hypothesized that a lower degree of cross-linking within the poly-
meric network of the NG might provide a more flexible polymeric nanostructure, and, therefore, an en-
hanced capability to physically encapsulate and release hydrophobic drugs.29,30 For these reasons, we 
chose PGA NG 1 for DOX loading.  
Finally, 1H NMR and FT-IR spectroscopies (Figures S1 and S2, ESI) confirmed the complete 
chemical coupling for PGA NG 1 by highlighting the appearance of the triazole peak and the disappear-
ance of the characteristic azide stretching band, respectively. 
 






Dh (nm)b PDIb 
NG 1 10/10 3 and 1 108 0.13 
NG 2 17/17 4 and 2 130 0.22 
NG 3 17/18 4 and 5 134 0.21 
NG 4 17/10 4 and 1 n.d. 0.48 
aFrom Table S1. bDetermined by DLS (mean intensity). n.d. Not determined due to multimodal distribution. Dh: hydrodynamic 





Figure 1. A. Representative 1H NMR spectra (D2O) of CuAAC coupling of PGA polymers, demonstrat-
ing the presence of the triazole peak. B. FT-IR-spectra of CuAAC cross-linking after coupling (black) 
compared to PGA-N3 (red). C. Hydrodynamic diameter (Dh) analysis in MilliQ H2O represented in num-
ber reveals small particle sizes of ~4 nm for PGA copolymers (PGA-N3 and PGA-Alkyne, Table S1 com-
pounds 1 and 3 respectively) whereas particle sizes larger than 100 nm were found for PGA NG and PGA-
DOX NG. 
 
Efficient DOX loading into PGA NGs 
We employed DOX as a model chemotherapeutic drug, given that it represents one of the current 




method based on electrostatic interactions between cationic DOX and the carboxylic acid groups of 
PGA.31 We estimated drug loading content (DLC) and drug loading efficiency (DLE) of DOX by UV-VIS 
measurements at λ= 488 nm (Figure S4) and calculated values according to Equations S1 and S2 (ESI). 
The typical DLC and DLE values (wt%) averaged at around 25 and 33, respectively, which agrees well 
with other studies reporting DOX entrapment by electrostatic interactions.32,33 
PGA NGs exhibited particle sizes of 225 nm with a PDI < 0.29 and good batch-to-batch reproduc-
ibility (in terms of size and PDI) as determined by DLS. Notably, we observed an increase in the negative 
z-potential measured for PGA-copolymers (~-20 mV) when they formed PGA NGs (~-49 mV), as previ-
ously observed with other PGA nanoparticles with a particle size around 100 nm.34 PGA-DOX NGs dis-
played a less negative z-potential (~-18 mV) due to the encapsulation of the positively charged DOX.  
Circular dichroism spectra of empty and loaded nanogels can be found in (Figure S5). In particular, the 
CD spectrum of PGA-DOX NGs shows the typical peaks of the DOX chromophore with its set of 𝛑𝛑 → 
𝛑𝛑* and n → 𝛑𝛑* transitions, and the characteristic negative band at 540 nm for DOX dimerization.35  
 
Figure 2. Morphology of cross-linked PGA NGs using various microscopic techniques. A) AFM images 




upper image). Scale-bar 500 nm in both upper and lower images. B). SEM images of cross-linked PGA 
NGs. Scale bars 500 nm. C) Cryo-TEM images of cross-linked PGA-DOX NGs at 0.1 mg/mL in MilliQ 
H2O. Scale bars 500 nm in the upper image and 100 nm in the lower magnification image. 
 
We next assessed the size, surface topology, and morphology of PGA and PGA-DOX NGs through 
various microscopy techniques, with the results mostly consistent with the data previously obtained by 
DLS. Cryo-TEM, SEM, and AFM micrographs of PGA NGs/PGA-DOX NGs revealed a spherical shape 
of the nanoparticles. Statistical analysis of AFM images showed a mean diameter of 98.2 ± 30 nm. Cryo-
TEM, SEM, and AFM micrographs of PGA NGs/PGA-DOX NGs revealed a spherical shape of the na-
noparticles (Figure 2). 
 
PGA-DOX NGs display Cathepsin B-triggered Drug Release and Efficient Internalization in TNBC 
Cells.  
Depending on the rational design strategy employed, multiple mechanisms mediate drug release 
from NGs. These include simple diffusion, degradation of NG structure, pH and temperature changes, 
counterion displacement or an external trigger4. PGA is a well-known biodegradable and biocompatible 
polypeptide, mainly degraded by cysteine proteases such as the lysosomal Cathepsin B.36,37 The degrada-
tion of PGA by lysosomal enzymes has been extensively studied in vitro although less extensively in 
vivo.38 In the design of our bioresponsive PGA-DOX NGs, the enzymatic degradation of the polymeric 
chain will trigger drug release at the desired site of action (tumor microenvironment and within tumor 
cells), thereby enhancing therapeutic efficiency and reducing unwanted side effects. Although other pro-
teases may play a role in the enzymatic degradation of PGA backbones, Cathepsin B has been identified 




provide an estimate of the in vivo biological performance of our constructs. Furthermore, we have previ-
ously demonstrated the Cathepsin B-dependent biodegradability of star-shaped and linear PGA poly-
mers.27 
Figure 3A establishes that degradation of the nanogel structure by Cathepsin B is the major drug release 
mechanism triggering a rapid release of DOX from NGs, with already 80% of drug release at 8 h post-
treatment. This fact validates the suitability of these systems for lysosomotropic DOX delivery and/or for 
triggering drug release in the TNBC tumor microenvironment where cathepsin B is also overexpressed, 
in particular, in those tumors with the worst prognosis.39,40 Release studies with the enzyme were per-
formed at pH 6, as Cathepsin B is a lysosomal enzyme and requires acidic pH and reductive environment 
to be active.27 Although in our experiments we reach a plateau at 80 % drug release, we envisage complete 
release in a more complex cellular environment, as PGA degradation will not only rely on cathepsin B 
but also in other proteases present. Another possible explanation of this incomplete release could derive 
from difficulties in DOX quantification in our experimental conditions due to a possible formation of a 
colloidal suspension of DOX upon release.  
PGA-DOX NGs show minimum drug release when incubated in mouse plasma for 24 hours, an indi-
cation of adequate plasma stability for i.v. administration. This fact can be presumably explained by the 
formation of a plasma-derived protein corona. Previous works have also noted altered drug release from 
NGs as a result of the protein corona, suggesting potential differences in in vitro or in vivo release pro-
files.41 The control drug release studies in buffer conditions show lower DOX release rate as compared to 
the one obtained with Cathepsin B. The similar release rates at pH 5.5 and 7.4 (Figure S6) could arise 
from the nanogel swelling and presence of the high ionic strength (150 mM) that may cause dissociation 
between the ionic complex DOX/COOH. pH responsiveness could be achieved if pH sensitive functional 
groups that deionize in the polymeric network are introduced, in this case pKa of PGA is around 5.534 
therefore such pH responsiveness at physiological pHs were not observed (Figure S6). Only very acidic 







Figure 3. A. Drug release profile of PGA-DOX NG in the presence of Cathepsin B (Cat B, triangles) and 
under physiological pH control conditions (PBS pH 7.4, circles) and plasma (diamonds) demonstrate a 
non-significant release in plasma and a burst release under enzymatic or hydrolytic conditions with a 
maximum of drug release of 80 % with Cathepsin B (n=3, data as mean ± SEM). B. Cell-associated 
fluorescence over time of PGA-NG DOX at 37 °C in the 4T1 murine breast cancer cell line suggests 
cellular uptake, indicative of co-operative mechanisms of internalization (n > 3, mean ± SEM). C. Con-
focal images of DOX (upper) and PGA-DOX NG (lower) uptake at 15 min post-treatment in 4T1 cells 
following a pulse-chase experiment (Blue-Hoechst 33342 for nuclei; Red-DOX associated fluorescence). 
The localization of DOX to the nucleus, while PGA-DOX NGs were absent, suggests altered internaliza-




Understanding the cellular internalization mechanisms employed by nanomedicines represents a 
mandatory step in the drug delivery field.42 Linear and branched PGAs follow endocytic mechanisms of 
internalization, and so represent suitable candidates for lysosomotropic drug delivery.27,34 Drug release 
from PGA-DOX NGs relies on the action of lysosomal endopeptidases, thereby requiring efficient cellular 
uptake following a lysosomotropic delivery route.  
To investigate whether PGA-DOX NGs, whose physico-chemical features differ from conven-
tional lineal PGA-drug conjugates, follow the same uptake mechanism, we performed live-cell in vitro 
studies. We employed flow cytometry (for the quantification of cell uptake) together with live-cell confo-
cal microscopy analysis (for the qualitative visualization of subcellular fate and pathway) in the 4T1 mu-
rine breast cancer cells (TNBC and with high metastatic potential). We observed a high and rapid inter-
nalization rate (represented by the cell associated fluorescence, Figure 3B) for PGA-DOX NG in 4T1 
cells at 37 °C. While we observed free DOX in the nucleus at 15 min at 37 °C (see Figure 3C, Figures S7, 
and S8), as expected for a DNA intercalator, we encountered PGA-DOX NGs co-localizing with the ly-
sosomes at a later timepoint, at 1 h post-treatment (Figure 3C, Figure S9). These data suggest that PGA-
DOX NGs exhibited a different internalization route and kinetics than the free form of DOX. Furthermore, 
confocal images suggested that PGA-DOX NGs allowed for increased drug uptake (when compared to 
free DOX). The fact that DOX encapsulated within our nanogels does not follow a diffusion mechanism 
of cell entry, but instead, an energy-dependent endocytic uptake mechanism and lysosomotropic traffick-
ing, indicates that DOX delivered this way escapes the drug-efflux pumps, the ATP-binding cassette 
(ABC) transporters located in the cell membrane, and thus, would avoid a potential drug-resistance.43-45 
The final fate of DOX in due time would be the nucleus as per its topoisomerase II defined target. 
PGA-DOX NGs exert In-vitro Antitumor Activity in TNBC Cells 
We next assessed the cytotoxic effects of PGA-DOX NGs in 4T1 cells compared to free DOX and 
the control PGA NG, the later showing absence of cytotoxicity up to the concentration tested. Overall, 




0.3102 and 0.1825 μg/mL eq. DOX, respectively (Figure 4A, Table S2). Apoptosis assays with Annexin 
V revealed a trend towards fewer apoptotic cells following treatment with PGA-DOX NGs compared to 
DOX during 72 h, although any differences failed to reach significance (Figure S10).  
 
 
Figure 4. A. Cell viability curves for IC50 determination in 4T1 cells after 72 hours of treatment with 
PGA NGs/PGA-DOX NGs measured by MTS assay shows similar in vitro antitumor activity of PGA-
DOX NG (green) when compared to free DOX (red). Unloaded PGA NGs evaluated at an equivalent 
polymer concentration of the PGA-DOX NG failed to exhibit toxicity at the concentrations evaluated 
(n>4 independent experiments with 6 replicates each, mean ± SEM). B-D. Cell cycle analysis using pro-
pidium iodide (PI) staining and flow cytometry. 4T1 cells were treated for 24 h (B), 48 h (C), and 72 h 
(D) at the IC50 values obtained by MTS assays (72 h). CTR: Control cells without treatment. Results are 
the mean ± SEM of three independent experiments with two replicates each. One-way ANOVA and Bon-
ferroni post hoc were used for comparison between groups. *P<0.05; **P<0.01; ***P<0.001; ns: non-
significant. 
 
Cell cycle analysis using propidium iodide (PI) staining and flow cytometry demonstrated a sim-




time points (24 h and 48 h of treatment Figures 4B and C, respectively), we observed statistically signif-
icant differences between DOX and PGA-DOX NGs. These differences became “normalized” over time, 
suggesting different kinetics in the mechanism of action that could be closely related to the different ki-
netics found for the internalization rate and drug bioavailability. Cell cycle analysis revealed that, as a 
general trend, both DOX and PGA-DOX NGs promoted cell accumulation in the G2/M phase to the det-
riment of G0/G1 when compared to untreated control 4T1 cells. These facts suggest a cell cycle arrest, 
which hinders cell division and ultimately leads to cell death, a finding that agrees with previous reports 
regarding the mechanism of action of DOX in vitro.46 
 
Injectable PGA-DOX NGs Prompt Significant Reductions in Primary Tumor Volume and Weight 
in a Mouse TNBC Model 
Our in vitro data encouraged us to evaluate our PGA-DOX NGs in a spontaneously metastatic 
TNBC orthotopic murine model.47 We inoculated animals in the mammary fat pad with 4T1 cells follow-
ing previously optimized protocols.48,49 Treatments began at day 8, a time point that coincided with the 
maximum enhanced permeability and retention effect50 when tumors sizes had reached ~0.1 cm3, to pro-
mote efficient tumor uptake. After intravenous injection through the tail vein (three doses every three 
days), we monitored tumor growth for 16 days. As additional controls, we employed free DOX and a 
PGA-DOX conjugate synthesized with a non-biodegradable linker that significant diminish DOX release 
in order to remark the importance of an adequate drug release profile as previously demonstrated.48,49 We 
used free DOX doses of 3 mg/kg due to previously observed toxicity with higher DOX doses;48,49  how-
ever, we could apply doses up to 10 mg/kg of DOX equivalents for PGA-DOX conjugate and PGA-DOX 
NGs without observed toxicity, which represents an advantage of the PGA formulations compared with 




We systematically evaluated the general aspect, behavior, body weight (Figure 5A), and post-mor-
tem major organ weights of all animals (Figure S11) to assess safety. Of note, we failed to observe signif-
icant animal weight or major organ weight alterations in response to any treatment (Figure 5A and Figure 
S11). At the experimental endpoint, PGA-DOX NGs significantly reduced the primary tumor volume 
(24% - see Figure 5B); however, we failed to observe any antitumoral effect for the control PGA-DOX 
conjugate, while free DOX treatment provided no statistically significant improvement over PBS treated 
controls (Figure 5B). The statistics included in Figure 5B imply non-significant differences between DOX 
and PGA-DOX NGs in this particular case. Moreover, only PGA-DOX NGs displayed statistically sig-
nificant decreases in tumor weight compared to PBS and PGA-DOX conjugate treatment (Figure 5C).  
 
 
Figure 5. A-B. Safety (A) and antitumor activity (B) expressed relative to bodyweight of PGA-DOX NG 




free DOX (3 mg/kg DOX-eq), and a PGA-DOX conjugate (10 mg/kg DOX-eq). Treatments were per-
formed at day 0 (tumor volume = 0.1 cm3), 3, and 6. Animals treated with PGA-DOX NG treatment 
exhibited a significant reduction in tumor volume (24%) compared to those treated with PBS or PGA-
DOX conjugate, with no significant loss in animal weight observed. DOX treatment reduced the tumor 
volume by up to 14% of PBS treated animals. One-way ANOVA and Bonferroni post hoc were used for 
comparison between groups at the endpoint. *P<0.05. C-D. Weight of tumors (C) and spleen (D) from 
orthotopic 4T1 breast tumor mice after sacrifice at day 15. Mice treated with PGA-DOX NG showed 
significant reductions in tumor and spleen weight compared to PBS and PGA-DOX conjugate. One-way 
ANOVA and Tukey post hoc were used for comparison between groups. *P<0.05; **P<0.01; 
***P<0.001. 
Splenic and hepatic erythropoiesis-induced acute splenomegaly characterizes this tumor 
model,50,51 and represents a collateral impact of tumor development.48 Encouragingly, both free DOX and 
PGA-DOX NG significantly reduced splenomegaly, as measured by alterations to spleen weight (Figure 
5D).  
PGA-DOX NG Treatment Promotes a Near-complete Reduction in Lung and Lymph Node Metas-
tases 
Lung and lymph node metastasis represent common complications in breast cancer patients and a 
particular concern in TNBC. The 4T1 orthotopic tumor model employed within this study develops spon-
taneous metastasis in the lungs and lymph nodes.48,50 When analyzing those metastatic sites post-treat-
ment, we discovered that PGA-DOX NGs exerted a very robust anti-metastatic effect in the lungs and the 
axillary lymph nodes (Figure 6A). We first detected lung micrometastasis around day three after cell in-
oculation, although we failed to find evident sub-pleural metastases until day 8 (day 0 of our treatment 
schedule).48,50 We observed the first signs of lymph node metastasis signs at day 13 (day 5 of our treatment 
schedule) in a less reproducible pattern when compared to lung metastasis. This lack of uniformity ex-
plains the higher variability observed in the determination of axillary lymph node metastasis (Figure 6A 
right) when compared to lung metastasis (Figure 6A left). We determined the number of 6-thioguanine-
resistant metastatic cells in the relevant organs after organ collection and digestion using Trypan Blue 




metastases (up to 80%) when compared to control, whereas free DOX failed to exert a significant effect. 
Moreover, PGA-DOX NG treatment almost completely suppressed axillary lymph node metastasis, while 
free DOX and the PGA-DOX control conjugate exerted moderate non-statistically significant effects (Fig-
ure 6B). 
Importantly, lungs from animals treated with PGA-DOX NGs weighed significantly less than 
lungs from control animals or animals treated with DOX or the PGA-DOX conjugate (Figure 6B). This 
finding represents another indication of effective anti-metastatic activity and the possible reduction of 
inflammation, which could inhibit tumor recurrence.  
 
Figure 6. The anti-metastatic activity of PGA-DOX NG in an orthotopic 4T1 breast tumor mice model in 
comparison with PBS-treated control, free DOX, and the PGA-DOX conjugate, as measured by Trypan 
Blue staining (A). PGA-DOX NGs exerted significant anti-metastatic activity in the lungs (left) when 
compared to animals treated with PBS, free DOX and control PGA-DOX conjugate. Inhibition of axillary 
lymph node (ALN) metastasis (right) was also significantly reduced following PGA-DOX NGs when 
compared to PBS controls. One-way ANOVA and Bonferroni post hoc were used for comparison between 
groups. *P<0.05 and **P<0.01 B) Weight of lungs extracted from orthotopic 4T1 breast tumor-bearing 
mice after sacrifice at day 15. Mice treated with PGA-DOX NG displayed a significant reduction in lung 
weight compared to PBS control, PGA-DOX conjugate, and free DOX treatment, with these findings 
related to the lower incidence of lung metastases. One-way ANOVA and Tukey post hoc were used for 
comparison between groups. *P<0.05. 
 
The observed anti-metastatic activity, as previously demonstrated with pH-responsive PGA-hyd-




3A) due to the presence of cathepsin B already at the tumor extracellular matrix,53,54 allowing DOX to 
exert its activity in tumor microenvironment after tumor accumulation by the EPR effect. Additionally, 
this could be partially explained by NGs size and deformability properties. It has been demonstrated by 
us and others that soft nanogels with hydrodynamic diameters between 100 and 200 nm have a strong 
localization in the lungs in the early time points after intravenous administration, as well as in the liver 
and spleen.55-57 Metastases result from the activities of multiple orchestrated pathways that provide cancer 
cells with the ability to migrate, access the bloodstream or lymphatic vessels, and eventually colonize 
distant sites. Lymph node metastases generally arise through the formation of new lymphatic vessels 
(lymphangiogenesis),58,59 whereas metastases to distant organs occur through new blood vessel formation 
(angiogenesis).60 The VEGF family proteins, among other important factors, regulate both processes,61 
and studies have positively correlated VEGF expression with tumor size, depth of invasion, lymphatic 
and venous invasion, and lymph node metastasis. Furthermore, VEGF has even been used for pathological 
staging and as a marker for recurrence in several cancers.62,63 Additionally, a recent report suggested the 
dependence of metastasis on components of the blood coagulation cascade such as thrombin64-66 or tissue 
factor (TF), although the exact mechanisms by which this occurs have yet to be fully elucidated. Indeed, 
studies have discovered TF overexpression in metastatic breast cancer cells when compared to non-met-






Figure 7. Effect of PGA-DOX NGs treatments in vascular endothelial growth factor (VEGF) and tissue 
factor (TF) expression in the tumors from orthotopic 4T1 breast tumor mice model using Western blotting 
(A) and quantification with ImageJ (B). Results derived from tumor samples extracted at the experimental 
endpoints compared with untreated controls (PBS) and free DOX. One-way ANOVA and Bonferroni post 
hoc were used for comparison between groups. *P<0.05. 
 
Results from Western blotting analyses (Figure 7) highlighted the significant decrease in TF ex-
pression in tumors deriving from PGA-DOX NG treated animals compared to the PBS control, but not 
when compared to free DOX; however, PGA-DOX NG treatment although showed a clear trend, failed 
to induce the significant inhibition of VEGF expression in tumors. These preliminary results suggest that 
the mechanism of action of our PGA-DOX NGs includes an important anti-metastatic component; there-




In this study, we report on the development of a new drug delivery platform comprising the first example 
of anionic chemically-crosslinked nanogels (NGs) exclusively formed from biodegradable and biocom-
patible polypeptides, in particular polyglutamates (PGA). We employed copper-catalyzed azide-alkyne 
cycloaddition (CuAAC) to prepare NGs in inverse miniemulsion with orthogonally derivatized PGAs, 
thus allowing control over size and dispersity. These bioresponsive PGA-DOX NGs displayed robust 
uptake by 4T1 cancer cells and significant DOX release when incubated with the enzyme Cathepsin B, 
thereby suggesting their potential therapeutic efficacy in TNBC treatment. Following PGA-DOX NG 
treatment in an orthotopic TNBC murine model, we observed a reduction in primary tumor growth and a 
significant reduction in lung and lymph node metastasis without any noted side toxicities. We also under-
took a preliminary mechanistic exploration that provides evidence of a potential modulation of the mo-




metastatic NG platform may represent a powerful tool for the treatment of advanced-stage breast cancer, 
such as many TNBC cases where primary tumor resection is not sufficient to block cancer progression. 
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Notes 






AFM, Atomic Force Microscopy, CD, Circular Dichroism; Dh, Hydrodynamic Diameter; DLC, Drug 
Loading Content; DLE, Drug Loading Efficiency; DLS, Dynamic Light Scattering; DOX, Doxorubicin; 
FT-IR, Fourier Transform Infrared Spectroscopy; NMR, Nuclear Magnetic Resonance; PBS, Phosphate 
Buffer Saline; PGA, Poly(glutamic acid); PI, propidium iodide; SEM, Scanning Electron Microscopy; 
TEM, Transmission Electron Microscopy; TF, Tissue Factor; TNBC, Triple Negative Breast Cancer; UV-
VIS, Ultraviolet-Visible; VEGF, Vascular Endothelial Growth Factor.  
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1. Materials  
All chemicals were reagent grade, obtained from Sigma- Aldrich, and used without further purification 
unless otherwise indicated. Poly (L-glutamic acid) (PGA) MW=10,500 Da, PDI 1.1 was purchased from 
Polypeptide Therapeutic Solutions (PTS, Valencia, Spain). Phenazine methosulfate (PMS), sodium 
citrate, and triton were supplied by Sigma (Spain). Dulbecco's Modified Eagle's Medium (DMEM), 
Leibovitz's L-15 medium, phosphate buffer saline (PBS), fetal bovine serum (FBS) Medium 200, low 
serum growth supplement (LSGS), and trypsin were purchased from Gibco. 3-(4,5-dimethylthiazol-2-yl)-
5- (3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) was supplied by Promega 
(Spain). Doxorubicin hydrochloride (DOX·HCl) was purchased from Yick-Vic Chemicals & 
Pharmaceuticals (China). Cathepsin B (CatB) from bovine spleen (lyophilized powder, ≥10 units/mg 
protein), Annexin V, and Propidium Iodide were obtained from Inmunostep (Spain). All solvents were of 
analytical grade and were used as received or dried and freshly distilled. Ultrapure water with a resistivity 
of 18 MΩ.cm was used in all aqueous preparations (MilliQ, Millipore). Chloroform-d1, 
dimethylsulfoxide-d6, and deuterium oxide were purchased from Deutero GmbH (Germany). Preparative 
size-exclusion chromatography (SEC) was performed using Sephadex G-25 superfine and PD MiniTrap 
G-10 ™ columns containing 2.1 ml of Sephadex™ G-10 (GE Healthcare, Spain). Dialysis was performed 
using Amicon Ultra-15 centrifugal tubes fitted with a 1, 3, 10, 30, 50, or 100 kDa molecular weight cut-
off (MWCO) regenerated cellulose membrane (Vivaspin®). Formvar precoated copper grids (400 mesh) 
were bought from Aname S. L (Spain). The 4T1 cell line was obtained from the ATTC®. 6-8 weeks 




2. Physico-Chemical Characterization 
NMR Spectroscopy. NMR spectra were recorded at 27°C (300K) on a Bruker AC 300 or Bruker DRX 
500 spectrometer. Data were processed with the software Mestrenova 6.2. Samples were prepared at the 
desired concentration in D2O.  
Circular Dichroism. CD Spectroscopy was performed with a J-815 CD Spectrometer (JASCO 
Corporation) using a Peltier thermostated cell holder (PTC-423, JASCO Corporation) with a recirculating 
cooler (JULABO F250, JASCO Corporation). A nitrogen flow (~2.7 L/min) was led through the 
spectrometer and controlled with a nitrogen flow monitor (Afriso Euro-Index). The samples were 
dissolved in double-distilled water (MilliQ H2O) at 0.1 mg/mL. Samples were measured repeatedly (n= 
3) in a quartz cuvette with d= 0.1 cm.  
Dynamic Light Scattering. DLS measurements were performed using a Malvern Zetasizer NanoZS 
instrument equipped with a 532 nm laser at a fixed scattering angle of 173°. Solutions of the polymers at 
1 mg/mL in PBS (to mimic physiological environment) were sonicated for 10 min and allowed to 
equilibrate for the required time, filtered through a 0.45 μm cellulose membrane filter, and measured. Size 
distribution was measured (radius, nm) for each compound per triplicate with n> 3 measurements. 
Automatic optimization of beam focusing and attenuation were applied for each sample.  
Z-Potential Measurements. Z-potential measurements were performed at 20°C using a Malvern 
Zetasizer NanoZS instrument, equipped with a 532nm laser using Disposable folded capillary cells 
(Malvern Instruments Ltd, Worcestershire, UK). Polymer solutions were prepared in 10 mM PBS pH 7.4. 
The solutions were filtered through a 0.45 μm cellulose membrane filter. Z-potential was measured for 
each sample per triplicate with n> 3 measurements. 
Fourier Transform Infrared Spectroscopy. IR spectra were recorded using Thermo Scientific 
Nicolet 380 FT-IR spectrometer with a spectral range 7800-350 cm-1, optical resolution (apodized) < 0.9 
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cm-1 resolution (standard) and peak-to-peak noise < 2.2∙10-5 abs. (> 22000:1) (1-minute scan). All 
samples analyzed were under solution or previously dissolved in DMF. The analysis was carried out at 
25 ˚C.  
Ultraviolet-Visible Spectroscopy. UV-VIS measurements were performed using JASCO V-630 
spectrophotometer at 25°C with 1.0 cm matched quartz cells and with a spectral bandwidth of 0.5 nm. In 
the case of nanogels, a Perkin Elmer Lambda 750 Spectrophotometer was employed. 
Scanning Electron Microscopy. SEM micrographs of the nanogels were acquired using a Quanta 200 
FEG Environmental SEM, in high vacuum with an accelerating voltage of 5.0 KV. A droplet of nanogel 
solution was placed onto the surface of a silicon wafer, air-dried for 20 mins, and then covered with a 4 
nm layer of chromium.  
Atomic Force Microscopy. A nanogel droplet was placed on a Mica sheet and allowed to dry 
overnight. AFM imaging was performed in air using a MultiMode 8 AFM equipped with a NanoScope V 
system (Veeco, Santa Barbara, USA) operated in tapping mode. Samples were analyzed using NanoWorld 
tips, Non-Contact/Tapping Mode-Long Cantilever (NCL-W), with a resonance frequency of 190 kHz and 
constant force of 48 N m-1. Statistical analyses were performed using NanoScope Analysis 1.3 software 
in a 5 x 5 µm image. Total Count: 514.00. Diameter: 98.16 nm. SD: 30.57 nm 
Cryo-Transmission Electron Microscopy. Specimens for the cryo-TEM observation of vitreous thin 
films were prepared using a "cryoplunge" cryo-fixation device (Leica EM GP, Germany), which enables 
rapid immersion in a cryogenic fluid (liquid ethane or propane). A typical support is a TEM copper grid 
(3 mm in diameter) recovered with a Lacey-type carbon film that contains regularly or randomly dispersed 
holes in which the aqueous dispersion is placed (Ted Pella Inc., USA). A glow discharged treatment is 
applied to the carbon film to render it hydrophilic, before the deposition of a 5 μl microdrop of the 
dispersion that is reduced in thickness by blotting with Whatman paper. The liquid film is placed in a 
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humidity-controlled chamber (which maintains a relative humidity of 97-99%) to prevent its evaporation 
until the TEM grid is projected into a cold liquid to enable the most efficient absorption of the sample 
heat. This liquid is ethane that has previously liquefied from gas by placing it in contact with the cold 
walls of a metal goblet plunged into liquid nitrogen. The direct use of liquid nitrogen is usually avoided 
because heat transfer is restricted by the existence of a thin intermediate layer of gas (the Leindenfrost 
effect). 2.5 ml of liquid ethane maintained at -174 °C are sufficient for sample preparation. Below this 
temperature, liquid ethane solidifies (at around -182.5°C), and while above this temperature, water 
crystallizes (at around -135°C). Finally, the objects of interest in the aqueous dispersion were embedded 
in the vitreous water film through the holes in the carbon film support. The TEM grids were mounted on 
a Gatan 626 Single Tilt Liquid Nitrogen Cryo Transfer Holder (Gatan, USA) equipped with a liquid 
nitrogen reservoir, and then transferred to the microscope (FEI, Tecnai Spirit G2) using a CT-3500 
cryotransfer system (Gatan, USA) designed to ensure that the frozen state of the sample is uninterrupted.  
3. Optimization of Polyglutamic Acid-based Nanogel Synthesis 
a) PGA Precursors Synthesis 
Alkyne and azide derivatized PGAs were synthesized in a previous step, according to Barz et al.1 and 
using a PGA of Mw 10,500 Da and PDI 1.1. We employed propargylamine and oligoethylene glycol azide 
residues for the alkyne and azide functionalization, respectively, to yield compounds S1-S5 (see Scheme 
S1 and Table S1). 
a) Poly(glutamic acid-co-EG(n)N3 glutamate), 1, 2 and 5: 1H NMR δH (300MHz, D2O): 4.28-4.07 
(1H, m), 3.65-3.51 (xH, m), 3.48 (2xH, t), 3.40-3.30 (2xH, m), 3.25 (2xH, d), 2.29 -2.00(2H, m), 1.98 -
1.65 (2H, m). *R: 8 for EG2, 20 for EG6. x: molar percentage of modification.  
b) Poly(glutamic acid-co-propargyl glutamate), 3-4: 1H NMR δH (300MHz, D2O): 4.30-4.02 (1H, m), 




Scheme 1. Alkyne and Azide functionalization of PGA.  
Table S1. Alkyne and Azide PGA precursors. 
Compound Description % Alkyne/Azide* MW KDa# 
1 PGA-coPGAPEG(6)N3 10 12.7 
2 PGA-coPGAPEG(6)N3 17 14.3 
3 PGA-coPGAPropargyl 10 10.7 
4 PGA-coPGAPropargyl 17 10.7 
5 PGA-coPGAPEG(2)N3 18 12.8 









b) Preparation of PGA NGs and DOX Loading 
 
Figure S1 Representative FT-IR-spectra of NG 1 (Table 2) confirming the disappearance of the azide 
asymmetric stretching band at 2124 cm-1. 
 















𝐷𝐷𝐷𝐷𝐷𝐷 (𝑤𝑤𝑤𝑤. %) =
𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑤𝑤 𝑎𝑎𝑜𝑜 𝑑𝑑𝑑𝑑𝑎𝑎𝑑𝑑 𝑖𝑖𝑎𝑎 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑑𝑑𝑛𝑛𝑛𝑛
𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑤𝑤 𝑎𝑎𝑜𝑜 𝑑𝑑𝑑𝑑𝑎𝑎𝑑𝑑 − 𝑛𝑛𝑎𝑎𝑎𝑎𝑑𝑑𝑛𝑛𝑑𝑑 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑑𝑑𝑛𝑛𝑛𝑛
𝑥𝑥100 
Equation 1. Drug loading content (DLC) 
 
𝐷𝐷𝐷𝐷𝐷𝐷 (𝑤𝑤𝑤𝑤. %) =
𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑤𝑤 𝑎𝑎𝑜𝑜 𝑑𝑑𝑑𝑑𝑎𝑎𝑑𝑑 𝑖𝑖𝑎𝑎 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑑𝑑𝑛𝑛𝑛𝑛
𝑤𝑤𝑎𝑎𝑤𝑤𝑎𝑎𝑛𝑛 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑤𝑤 𝑎𝑎𝑜𝑜 𝑜𝑜𝑛𝑛𝑛𝑛𝑑𝑑𝑖𝑖𝑎𝑎𝑑𝑑 𝑑𝑑𝑑𝑑𝑎𝑎𝑑𝑑
𝑥𝑥100 
Equation 2. Drug loading efficiency (DLE) 
c) Copper Removal Efficiency and Related Cytotoxicity 
To remove copper catalyst traces, a previously described procedure for CuAAC coupling of polymers 
with carboxylic acids was followed 2. Briefly, during the aqueous purification, the NGs were washed with 
a solution of aq. HCl pH 3 (2 × 30 ml), followed by saturated NaHCO3 (2 × 30 ml), and finally with H2O 
(4 × 30 ml). The acidic conditions should protonate the carboxylic acid groups, therefore hampering their 
complexation with remaining copper ions. To probe the efficiency of this procedure, MTT assays of the 
NGs washed either only with H2O or submitted to acidic treatment were carried out. As depicted in Figure 
S3, a remarkably lower level of toxicity was observed for those NGs submitted to the copper removal 
treatment. Cell viability was assessed after 48 h exposure to different dilutions of the compounds to cells 
by MTT test. A549 cells were obtained from the Leibnitz Institute DSMZ – German Collection of 
Microorganisms and Cell Cultures and were routinely grown at 37°C and 5% CO2 in DMEM (Thermo 
Fisher Scientific) with 10% FBS (FBS Superior, Merck) and 1% penicillin/streptomycin (Thermo Fisher 
Scientific). 10,000 cells/well were seeded into 96 well plates and grown overnight. The next day, the 
medium was removed and replaced with 100 µL/well fresh medium containing 10-fold serial dilutions of 
the test compounds and incubated for 48 h at 37 °C and 5% CO2. Then, the supernatant was removed, 
and 100 µL/well fresh medium containing 10µL per well MTT (5 mg/ml in PBS, Millipore Sigma) was 
added and incubated for 4 h at 37 °C, removed again, and the formazan crystals were dissolved in 100 
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µL/well isopropanol with 0.04 M HCl while shaking. Absorbance was read at 570 nm in a Tecan Infinite 
M200 Pro microplate reader. Average absorbance values from duplicate wells of cells treated with the 
test compounds were divided by average absorbance values of wells containing untreated cells to obtain 






























Figure S3. Cytotoxicity of PGA NGs with and without copper removal treatment against A549 cells 
measured by MTT assay 
 
4. Biological Methods 
Cell Culture protocols. 4T1 cells were cultured in RPMI-1640 media supplemented with 10% FBS. 
Cells were maintained at 37°C in an atmosphere of 5% carbon dioxide and 95% air. The medium was 
replaced every 2-3 days and underwent passage once weekly when 80% of cell confluence was reached. 
MTS assay for Cell Viability. Cells were seeded in sterile 96-well microtitre plates at a cell density 
of 6,250 cells/cm2 for 4T1. Plates were incubated for 24 h, and compounds (sterilized under UV-light) 
were then added to give a final concentration of 0.01 to 50 μg/mL eq-DOX (0.4 to 200 μg/mL polymer). 
After 72 h of incubation, MTS/PMS (20:1) (10 μL of manufacturer solution) was added to each well, and 
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the cells were incubated for a further 2 h. The optical density of each well was measured at 490 nm. Plates 
were read spectrophotometrically using a Victor2WallacTM plate reader. The absorbance values were 
represented as the percentage of cell viability taken as 100% cell viability of untreated control cells. N>4 
independent experiments, with 6 replicates each. 
Cellular Uptake by Flow Cytometry. 4T1 cells were seeded in 6-well plates at a density of 6,900 
cell/cm2 (1 ml cell suspension per well) and allowed to adhere for 24 h. In binding experiments conducted 
at 4°C, cells were pre-incubated at this temperature for 30 min before the start of the experiment. For both 
experiments, 4°C and 37°C, the cathepsin B inhibitor CA-074 (0.4 μL from a solution of 5 μM to reach a 
final concentration of 2 μM) was added 30 min before the addition of the NG. Then, 10 μL of DOX-
loaded NG (12 μg/mL eq. DOX final concentration) were added at different time points from 0 to 300 
min. Meanwhile, cells were incubated either at 37°C or 4°C for each experiment. Finally, cells were 
placed on ice to stop energy-dependent mechanisms and washed twice with cold PBS-BSA 0.1%. (PBS 
supplemented with Bovine Serum Albumin (BSA)). Then cells were suspended in 0.5 ml of cold PBS 
using a scraper. Finally, the cell pellet was placed in flow cytometer tubes. Cell-associated fluorescence 
was then analyzed using a Becton Dickinson FACS Calibur cytometer (California, USA) equipped with 
an argon laser (488 nm) and emission filter for 550 nm. Data collection involved 10,000 counts per 
sample, and data were analyzed using CELLQuestTM version 3.3 software. Data are expressed by plotting 
the cell-associated fluorescence, which is the result of the % of positive cells by multiplied by the mean 
fluorescence. CAF= % positive cells*mean fluorescence/100. Cells incubated without polymer were used 
to account for the background fluorescence.  
Statistical Analysis. Data from the experiments were analyzed using two-way ANOVA and 
Bonferroni post hoc. In all cases, we considered differences to be significant when p***<0.001; p**<0.01; 
p*<0.05; ns: non-significant. 
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Confocal Fluorescence Microscopy for Live-cell Imaging. For live-cell imaging, 4T1 cells were 
seeded in 6-well plates at a density of 6,900 cell/cm2 (1 ml cell suspension per well) on glass-bottom 
culture dishes (1 cm2 Petri plate) and allowed to seed for 24 h at 37°C. First, the cathepsin B inhibitor 
CA-074 (0.4μL from a solution of 5 μM to reach a final concentration of 2 μM) was added 30 min prior 
to the addition of the NG. Then, 10μL of DOX-loaded NG (12 μg/mL eq DOX final concentration), as 
well as the equivalent concentration of DOX, were added, and the cells were incubated for different at 
different time points (15 min, 30 min, 1 h, and 2 h at 37°C, and 30 min at 4ºC). 30 min before washing 
the cells with PBS-BSA 0.1%, the nuclear marker Hoechst (1 μL from a solution 5 mM), and the 
lysosomal marker Lysotracker Green (10 μL from a solution of 100 μM) were added to identify possible 
colocalization and therefore establish an endocytic pathway. Finally, cells were washed with PBS-BSA 
0.1%. Then, the glass was removed and placed on the microscope chamber with fresh media containing 
2 μM of CA-074 inhibitor. Samples were analyzed under the microscope. Images were captured with an 
inverted DM IRE2 microscope equipped with a λ-blue 60 x oil immersion objective and handled with a 
TCS SP2 system, equipped with an acoustic optical beam splitter (AOBS). Excitation was performed with 
an argon laser (Lysotracker Green 496 nm), an HeNe laser (DOX 561 nm), and a blue diode (Hoechst 405 
nm). Images were captured at an 8-bit greyscale and processed with LCS software (version 2.5.1347a, 
Leica Germany) containing multicolor, macro, and 3D components. Control cells that followed the same 
incubation time were also analyzed to establish the autofluorescence, as well as cells treated only with 
Hoechst or Lysotracker Green. 
Annexin V by Flow Cytometry. 4T1 cells were seeded in 6-well plates at a density of 5,900 cell/cm2 
(1mL cell suspension per well) and allowed to adhere for 24 h. Compounds (sterilized under UV-light) 
were then added at their calculated IC50 value. After 72 h of incubation, the media was removed and 
stored. Plates were washed twice with sterile PBS and incubated with 100 μL of trypsin for 5 minutes. 
After that time, the trypsin was inactivated with previously collected media, and the cell suspension was 
centrifuged at 400g for 7 minutes. The pellet was then resuspended in Annexin V buffer, transferred to 
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flow cytometry tubes, and incubated with 5 μL of commercial Annexin V-FITC for 20 minutes. Samples 
without Annexin V staining were used to determine autofluorescence, whereas untreated samples were 
used as controls. Samples were then analyzed using a Becton Dickinson FACS Calibur cytometer 
(California, USA) equipped with an argon laser (488 nm) and emission filter for 550 nm. Data collection 
involved 10,000 counts per sample, and data were analyzed using CELLQuestTM version 3.3 software. 
Cell Cycle by Flow Cytometry. 4T1 cells were seeded in 6-well plates at a density of 5,900 cell/cm2 
(1mL cell suspension per well) and allowed to adhere for 24h. Compounds (sterilized under UV-light) 
were then added at their calculated IC50 value. After 72 h of incubation, the media was removed and 
centrifuged at 400 g for 7 minutes while the cell monolayer was kept with PBS. The pellet was 
resuspended in 500 μL of hypotonic buffer containing sodium citrate, triton, RNase, and Propidium 
Iodide, and incubated for 24 h at 4 ºC. Samples were kept at 4 ºC until they were analyzed. Samples 
without PI staining were used to determine autofluorescence, whereas untreated samples were used as 
controls. Samples were analyzed using a Becton Dickinson FACS Calibur cytometer (California, USA) 
equipped with an argon laser (488 nm) and emission filter for 550 nm. Data collection involved 10,000 
counts per sample, and data were analyzed using CELLQuestTM version 3.3 software.  
Statistical Analysis. Data from the experiments were analyzed using two-way ANOVA and 
Bonferroni post hoc. In all cases, we considered differences to be significant when p***<0.001; p**<0.01; 
p*<0.05; ns: non-significant. 
Tumor model. In vivo antitumor activity evaluation of PGA-DOX NG in 4T1 murine orthotopic 
model. Animal experiments were performed per the European Communities Council Directive 
(86/609/ECC) guidelines and by Spanish Royal Decree 1201/2005. All the experimental procedures were 
approved by the Institutional Animal Care and Use Committee and performed by accredited and trained 
staff. Food and water were provided ad-libitum during the whole experiments in all cases, and the general 
aspect, behavior, and body weight were evaluated daily from the beginning of the experiment to ensure 
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animal welfare. 6-8-week-old female BALB/c mice used for all experimental procedures were purchased 
from Envigo Laboratories Inc. (Spain, EU). 4T1 tumors were induced by the intradermal injection of 5 x 
105 4T1 cells suspended in 100 µl of Matrigel (Extracellular Matrix gel 354234 BD at 20% diluted in 
RPMI media +10% inactivated serum) in the second left mammary fat pad under inhalatory anesthesia 
(2.5% sevoflurane in 100% oxygen) 3. Tumors were morphometrically evaluated daily with an electronic 
caliper, and tumor volumes were obtained by considering tumor shape as spheroids4. Eight days after 
tumor implantation, when the tumor size reached 0.1 cm3, mice were split into representative groups. 
Treatments were dissolved in PBS and immediately injected intravenously (i.v.) with three single doses 
of 10 mg/Kg Dox equivalents in the case of the NGs every three days. Free Dox dissolved in saline was 
administered at 5 mg/kg as free drug control, following the same schedule. Tumors were measured with 
a caliper, and volumes were obtained considering them to be spheroids. Once tumors reached 1.0 cm3 or 
16 days after the first treatment, mice were sacrificed under CO2 atmosphere and blood, and tumors and 
major organs were collected for molecular analysis. Treatment safety was evaluated by tracking body 
weight and comparisons with control and healthy animals. The mice under study were examined daily in 
the search for any pain-related behavior or conduct modification.  
Anti-metastatic activity in the Lung and axillary lymph nodes. Lung metastasis was evaluated 
following a previously described protocol5 with several improvements described in Arroyo-Crespo et al..3 
Lungs were removed immediately after animal sacrifice and washed in PBS. Tissues were then transferred 
to a 6-well plate previously filled with 3 ml of cold Hank's Balanced Salt Solution 1X (HBSS - Gibco) 
and washed twice. Over a new empty 6-well plate, organs were mixed with surgical scissors for 2 min, 
and 2.5 ml of cold collagenase Type IV (Gibco 17104-019) was added to each well. The tissue mixture 
was transferred into a 15 ml falcon tube and incubated at 4°C for 90 min in a rotatory shaker at maximum 
speed. Once the digestion was finished, the largest tissue pieces were broken down, and the final mixture 
was filtered by gravity through a 70 µm nylon filter (Fisher). The filtered suspension was collected by 
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adding 5 ml of HBSS 1X in the falcon and then centrifuged at 1,500 rpm (10°C, 5 min). The supernatant 
was removed, and the pellet was washed twice with 10 ml of HBSS, and the pellet was then suspended in 
10 ml of medium (RPMI1640 + 10% FBS + penicillin/streptomycin + fungizone) and seeded in six-well 
plates (1.4 ml each). The cells were incubated at 37ºC under 5% CO2, allowing for consistent growth. 
After five days, every well was washed three times with PBS. 6-thioguanine resistant-cells adhered to the 
plate, and other cells could be easily removed. 2 ml of fresh medium and 2 µl of 6-thioguanine were added 
back, and the incubation was allowed to continue. Eleven days after seeding, cells were washed twice 
with PBS, trypsinized (700 µl of trypsin), and resuspended in 800 µl of the medium. Finally, cells were 
counted with trypan blue or crystal violet in a dilution according to the degree of confluency.  
Western Blot. Western blot analysis was performed to evaluate essential protein from treated tumors 
after 16 days of treatment in the 4T1 model. Tumors were homogenized in a mortar with liquid nitrogen 
and proteins extracted using a Protein extraction kit from Millipore Corporation following the 
manufacturer's instructions. Protein content was determined by Bradford assay. 100 µg protein was then 
mixed with 5x SDS sample buffer, boiled for 7 min at 95°C to denaturize the protein, and separated 
through 8% SDS-PAGE gels. After electrophoresis, the proteins were transferred to PVDF membranes 
(Amersham Pharmacia Biotech, UK) by electrophoretic transfer. The membranes were blocked in 5% 
skim milk for 2 h, rinsed, and incubated overnight at 4ºC with the following primary antibodies: TF 
(1:1000) and VEGF (1:1000) from Santa Cruz Biotechnology Inc. and β-actin (1:10,000) from Sigma 
Aldrich. Excess antibody was then removed by washing the membrane in PBS/0.1% Tween 20, and the 
membranes were incubated for 1 h with horseradish peroxidase-conjugated secondary antibodies: goat 
anti-mouse IgG or donkey anti-rabbit IgG (1:5,000) (Santa Cruz Biotechnology Inc., Santa Cruz, CA, 
USA). After washes in PBS/0.1% Tween 20, immunodetection was performed with the use of the ECL 
Western blotting detection system (Amersham Pharmacia Biotech, UK), according to the manufacturer's 
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instructions. Relative protein levels were quantified by densitometry with ImageJ software. Results were 
standardized using β-actin expression as the reference.  
Statistical Analysis. Data from the experiments were analyzed using two-way ANOVA and 
Bonferroni post hoc. In all cases, we considered differences to be significant when p***<0.001; p**<0.01; 




4. Additional Supporting Figures 
4.1. Physicochemical Characterization 
 






Figure S5. Comparison of CD spectra of PGA precursors, PGA NGs (green), and PGA-DOX NGs 
(red). Both the regions from 205 to 255 nm (A) and from 350 to 700 nm (B) show the influence of DOX 
in the random coil secondary structure of the gel. The CD spectrum of PGA-DOX NGs shows the typical 
peaks of the DOX chromophore with its set of 𝛑𝛑 → 𝛑𝛑* and n → 𝛑𝛑* transitions, and the characteristic 




Figure S6. Drug release profile of PGA-DOX NG at different pH control conditions (pH 5.5, squares, 
pH 7.4, circles) at different time points (n=3, data as mean ± SEM).  
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4.2. Cell-based Assays 
 
 
Figure S7. Confocal images of Dox cellular uptake in 4T1 cells at different time points a pulse-chase 






Figure S8. Confocal images of PGA-Dox NG cellular uptake in 4T1 cells at different time points a 






Figure S9. Confocal images of PGA-Dox NG uptake at 1h post-treatment in 4T1 cells following a 
pulse-chase experiment (Blue-Hoechst 33342 for nuclei; Red-Dox associated fluorescence, Green-
LysoTracker Green). Colocalization with the LysoTracker marker was observed (merged in yellow). 
White triangles highlight representative colocalization. 
 
Table S2. IC50 values of free DOX and PGA-DOX NG in 4T1 cells, 72 h of treatment, as determined 
using GraphPad Prism 5 using non-linear regression to fit the data of the MTS assays to the log(inhibitor) 
vs. response (variable slope).  
Compound IC50 (μg/mL eq. DOX) 
Free DOX 0.1824 






















Figure S10. % Annexin V positive cells after 72h of incubation, as measured by flow cytometry using 
Dox and PGA-Dox NGs at the IC50 obtained for MTS assays. Results are the mean ± SEM of three 
independent experiments with two replicates each. A t-test was used for comparison between groups. The 
results were not statistically significant. 
 
 


























Figure S11. Weight of critical organs (heart, kidney, and liver) from orthotopic 4T1 breast tumor mice 
after sacrifice at day 15. Non-significant differences were found after one-way ANOVA and Bonferroni 
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